Pay in 4 interest-free payments of $7.03 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
The phase 3b, open-label, randomized controlled trial enrolled 751 adults with obesity or overweight plus at least one weight-related comorbidity such as hypertension, dyslipidemia, or sleep apnea
Administration of 1000 mg/kg/day myricetin (low dose), but not higher dose levels, caused a statistically significant increase in DNA damage in the duodenum of female mice as measured by the Comet assay
Important Note: While both drugs are effective, patient response can vary
Medications containing semaglutide marketed for type 2 diabetes or weight loss
Triple agonists like retatrutide are emerging as next-generation options with potentially different side effect profiles
US$ 22.33
US$ 22.48
US$ 24.10
US$ 27.30
US$ 26.97
